Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

JNJBullishIndustry Newsnews

High materiality8/10

Johnson & Johnson's ICOTYDE shows durable psoriasis clearance in high-impact sites

Oct 2, 2026, 6:12 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Durable two-year efficacy signals in high-impact psoriasis sites strengthen JNJ's pipeline narrative; potential for near-term investor attention and pipeline monetization, with additional upside if regulatory timelines advance.

AI summary

What happened, with direct paths to the underlying reporting

Johnson & Johnson reported two-year ICONIC-TOTAL results for ICOTYDE, a targeted oral IL-23 receptor blocker, showing sustained clearance at Week 112 in scalp, genital, and hand/foot psoriasis with favorable safety. The data may support expansion into high-impact sites and future regulatory filings, potentially strengthening JNJ's psoriasis franchise and competitive positioning against oral and biologic therapies.

Two-year ICONIC-TOTAL data show durable ICOTYDE skin clearance.
High-site clearance: 60% scalp, 89% genital at Week 112.
Genital psoriasis 89% and hand/foot clearance 63% notable.
ICOTYDE safety aligned with prior profiles; no new signals.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Johnson & Johnson's ICOTYDE shows durable psoriasis clearance in high-impact sites

TREMFYA Demonstrates MRI-confirmed Axial PsA Benefit; Growth Potential for JNJ

Caplyta Phase 3 success could expand JNJ bipolar mania label

FDA Expands J&J Drug Label for Rare Blood Disorder, Potentially Boosting Sales

JNJ expands oncology pipeline with $1B Firefly acquisition and Sail Biomedicines tie-up